HDAC6 and neoplasm: Genetic or pharmacologic disruption of HDAC6 in CAFs delays tumor growth, inhibits tumor recruitment of MDSCs and Tregs, alters macrophage phenotype switch, and increases CD8+ and CD4+-T cell activation in vivo [159].